UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

Medicines UK Urges Building On Deal With Further Regulatory And Supply Pacts

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

The UK and India have struck a free trade agreement (Shutterstock)

More from Regulation

More from Strategy